Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the
diameter of the pancreatic duct when used during Multidetector Computed Tomography
(MDCT) of the pancreas.
2. To demonstrate that RG1068-enhanced MDCT improves image quality of the pancreas in
patients with chronic pancreatitis.
3. To evaluate if RG1068 enhanced MDCT results in improved delineation of structural
abnormalities of the pancreatic duct as compared to non-enhanced MDCT.